Celularity, Inc. (CELU)
1.41
-0.02
(-1.74%)
USD |
NASDAQ |
Sep 11, 16:00
1.43
+0.02
(+1.42%)
After-Hours: 20:00
Celularity Enterprise Value : 109.20M for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 109.20M |
| September 10, 2026 | 109.92M |
| September 09, 2026 | 110.06M |
| September 08, 2026 | 112.95M |
| September 04, 2026 | 116.99M |
| September 03, 2026 | 121.31M |
| September 02, 2026 | 122.18M |
| September 01, 2026 | 122.75M |
| August 31, 2026 | 121.89M |
| August 28, 2026 | 114.10M |
| August 27, 2026 | 129.10M |
| August 26, 2026 | 93.93M |
| August 25, 2026 | 91.63M |
| August 24, 2026 | 90.88M |
| August 21, 2026 | 91.61M |
| August 20, 2026 | 90.66M |
| August 19, 2026 | 90.97M |
| August 18, 2026 | 89.78M |
| August 17, 2026 | 88.61M |
| August 14, 2026 | 88.60M |
| August 13, 2026 | 88.59M |
| August 12, 2026 | 88.44M |
| August 11, 2026 | 88.73M |
| August 10, 2026 | 88.34M |
| August 07, 2026 | 88.74M |
| Date | Value |
|---|---|
| August 06, 2026 | 88.23M |
| August 05, 2026 | 89.71M |
| August 04, 2026 | 88.82M |
| August 03, 2026 | 87.58M |
| July 31, 2026 | 86.86M |
| July 30, 2026 | 88.15M |
| July 29, 2026 | 87.86M |
| July 28, 2026 | 90.46M |
| July 27, 2026 | 90.20M |
| July 24, 2026 | 90.17M |
| July 23, 2026 | 90.45M |
| July 22, 2026 | 91.03M |
| July 21, 2026 | 91.90M |
| July 20, 2026 | 91.03M |
| July 17, 2026 | 91.04M |
| July 16, 2026 | 90.69M |
| July 15, 2026 | 91.03M |
| July 14, 2026 | 90.31M |
| July 13, 2026 | 90.31M |
| July 10, 2026 | 89.89M |
| July 09, 2026 | 90.10M |
| July 08, 2026 | 89.58M |
| July 07, 2026 | 89.49M |
| July 06, 2026 | 91.61M |
| July 02, 2026 | 86.41M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Tenax Therapeutics, Inc. | -58.55M |
| Manhattan Scientifics, Inc. | -- |
| Exicure, Inc. | 7.206M |
| Century Therapeutics, Inc. | 269.22M |
| Absci Corp. | 1.211B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -24.36M |
| Revenue (Quarterly) | 4.104M |
| Total Expenses (Quarterly) | 28.47M |
| EPS Diluted (Quarterly) | -0.8477 |
| Gross Profit Margin (Quarterly) | -123.6% |
| Profit Margin (Quarterly) | -593.6% |
| Earnings Yield | -254.2% |
| Normalized Earnings Yield | -225.67 |